NEXTSTELLIS will compete in the short-acting combination hormonal contraceptive
(estrogen and progestin) market which is valued at US$3.5 billion1
. Nearly 10 million
American women use combination oral contraceptives, patches or vaginal rings every
day. Of these contraceptives, more than 99% contain ethinyl estradiol, a synthetic
estrogen that binds widely to all estrogen receptors in the body.E4 acts differently than other estrogens and is the first natural estrogen with selective
action in tissues focusing on those needed to support contraceptive efficacy, cycle
control, and other beneficial effects of estrogen. Its unique pharmacologic profile includes
excellent oral bioavailability and a long half-life2
NEXTSTELLIS® ORAL CONTRACEPTIVE
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.27 |
Change
-0.100(1.36%) |
Mkt cap ! $618.4M | |||
| Open | High | Low | Value | Volume |
| $7.38 | $7.40 | $7.22 | $619.2K | 85.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5080 | $7.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.30 | 389 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$7.27 |
Change
-0.100 ( 0.69 %) |
||||
| Open | High | Low | Volume | ||
| $7.40 | $7.40 | $7.22 | 17278 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| MYX (ASX) Chart |